Still looks rather controversial. With an independent agency as well as external experts  (which means they are also independent) not willing to endorse the drug is a bit dubious. Biogen obviously wants their drug approved despite “mixed data” because they’ve already spent millions on R&D and FDA trials…so for the sake of patients hopefully the risks would not be too much for the suggested benefits.